Literature DB >> 9406168

A calcium stimulated cysteine protease involved in isoproterenol induced cardiac hypertrophy.

G D Arthur1, A N Belcastro.   

Abstract

The purpose of this study was to test the relationship between biochemical and functional changes accompanying beta-agonist induced cardiac hypertrophy and the activation of a calcium stimulated cysteine protease. Because the ultrastructural and ionic changes accompanying beta-agonist induced cardiac hypertrophy are reminiscent of the actions of the calcium activated neutral protease, calpain, it was hypothesized that lowering calpain activity (by the use of an exogenous inhibitor(s)) would reduce the extent of hypertrophy. Rats (275-300 g) were randomly assigned to either a control, beta-agonist (iso) or cysteine protease inhibitor (E64c) group. Isoproterenol administration (1 mg/kg) resulted in changes for ventricular weight to body weight ratio (increases 19%), ventricular [RNA] (increases 105.6%), rate of pressure development (increases 22% for +dP/dt) and maximum developed left ventricular pressure (increases 19%) (p < 0.05) after 3 days. Calpain-like activity (assessed by microplate method) increased by 45% (p < 0.05), while [cAMP] returned to control levels (following a transient rise at 1 day; 606.03 +/- 124.1 pmol/g/wet/wt to 937.9 +/- 225 (p < 0.05)). E64c (administered 1 h prior to iso) reduced the extent of hypertrophy, from 19 to 12%, and prevented the increases in; total [RNA], left ventricular function, the initial [cAMP] increase and calpain-like activity. It is concluded that a calcium stimulated cysteine protease(s), such as calpain, may be involved in the biochemical and functional changes associated with isoproterenol induced cardiac hypertrophy.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9406168

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  24 in total

1.  Isoproterenol-induced cardiac hypertrophy: modifications in characteristics of beta-adrenergic receptor, adenylate cyclase, and ventricular contraction.

Authors:  J Tse; J R Powell; C A Baste; R E Priest; J F Kuo
Journal:  Endocrinology       Date:  1979-07       Impact factor: 4.736

Review 2.  Contribution of calcium-activated neutral protease to the degradation process of ischemic heart.

Authors:  T Toyo-oka; M Morita; W S Shin; Y Okaimatsuo; T Sugimoto
Journal:  Jpn Circ J       Date:  1991-11

3.  Regulation of ribosomal DNA transcription during contraction-induced hypertrophy of neonatal cardiomyocytes.

Authors:  R D Hannan; J Luyken; L I Rothblum
Journal:  J Biol Chem       Date:  1996-02-09       Impact factor: 5.157

Review 4.  Growth and hypertrophy of the heart: towards an understanding of cardiac specific and inducible gene expression.

Authors:  M van Bilsen; K R Chien
Journal:  Cardiovasc Res       Date:  1993-07       Impact factor: 10.787

5.  Skeletal muscle calcium-activated neutral protease (calpain) with exercise.

Authors:  A N Belcastro
Journal:  J Appl Physiol (1985)       Date:  1993-03

6.  Positive regulation of mu-calpain action by polyphosphoinositides.

Authors:  T C Saido; M Shibata; T Takenawa; H Murofushi; K Suzuki
Journal:  J Biol Chem       Date:  1992-12-05       Impact factor: 5.157

7.  Protective effect of the protease inhibitor leupeptin against myocardial stunning.

Authors:  Y Matsumura; H Kusuoka; M Inoue; M Hori; T Kamada
Journal:  J Cardiovasc Pharmacol       Date:  1993-07       Impact factor: 3.105

8.  Influence of isoproterenol on contractile protein function, excitation-contraction coupling, and energy turnover of isolated nonfailing human myocardium.

Authors:  G Hasenfuss; L A Mulieri; B J Leavitt; N R Alpert
Journal:  J Mol Cell Cardiol       Date:  1994-11       Impact factor: 5.000

9.  Postischemic administration of AK275, a calpain inhibitor, provides substantial protection against focal ischemic brain damage.

Authors:  R T Bartus; K L Baker; A D Heiser; S D Sawyer; R L Dean; P J Elliott; J A Straub
Journal:  J Cereb Blood Flow Metab       Date:  1994-07       Impact factor: 6.200

10.  Measurement of rapidly exchangeable cellular calcium in the perfused beating rat heart.

Authors:  D R Hunter; R A Haworth; H A Berkoff
Journal:  Proc Natl Acad Sci U S A       Date:  1981-09       Impact factor: 11.205

View more
  17 in total

1.  Potential role of high molecular weight calmodulin-binding protein in cardiac injury.

Authors:  Anuraag Shrivastav; Rajendra K Sharma
Journal:  Int J Angiol       Date:  2009

Review 2.  Tear me down: role of calpain in the development of cardiac ventricular hypertrophy.

Authors:  Cam Patterson; Andrea L Portbury; Jonathan C Schisler; Monte S Willis
Journal:  Circ Res       Date:  2011-08-05       Impact factor: 17.367

3.  Calpain, calpastatin activities and ratios during myocardial ischemia-reperfusion.

Authors:  D Enns; M Karmazyn; J Mair; A Lercher; J Kountchev; A Belcastro
Journal:  Mol Cell Biochem       Date:  2002-12       Impact factor: 3.396

Review 4.  Exercise-induced muscle injury: a calpain hypothesis.

Authors:  A N Belcastro; L D Shewchuk; D A Raj
Journal:  Mol Cell Biochem       Date:  1998-02       Impact factor: 3.396

5.  Molecular Determinants of Calpain-dependent Cleavage of Junctophilin-2 Protein in Cardiomyocytes.

Authors:  Ang Guo; Duane Hall; Caimei Zhang; Tianqing Peng; Jordan D Miller; William Kutschke; Chad E Grueter; Frances L Johnson; Richard Z Lin; Long-Sheng Song
Journal:  J Biol Chem       Date:  2015-06-10       Impact factor: 5.157

6.  Transcriptional and translational regulation of calpain in the rat heart after myocardial infarction--effects of AT(1) and AT(2) receptor antagonists and ACE inhibitor.

Authors:  S Sandmann; M Yu; T Unger
Journal:  Br J Pharmacol       Date:  2001-02       Impact factor: 8.739

Review 7.  Role of various proteases in cardiac remodeling and progression of heart failure.

Authors:  Alison L Müller; Naranjan S Dhalla
Journal:  Heart Fail Rev       Date:  2012-05       Impact factor: 4.214

8.  Effect of U50,488H, a κ-opioid receptor agonist on myocardial α-and β-myosin heavy chain expression and oxidative stress associated with isoproterenol-induced cardiac hypertrophy in rat.

Authors:  Amardeep Jaiswal; Santosh Kumar; Sandeep Seth; Amit Kumar Dinda; Subir Kumar Maulik
Journal:  Mol Cell Biochem       Date:  2010-08-21       Impact factor: 3.396

Review 9.  The pathogenic activation of calpain: a marker and mediator of cellular toxicity and disease states.

Authors:  P W Vanderklish; B A Bahr
Journal:  Int J Exp Pathol       Date:  2000-10       Impact factor: 1.925

10.  Differential effects of calpain inhibitors on hypertrophy of cardiomyocytes.

Authors:  Jay R Pollack; Richard C Witt; Jeffrey T Sugimoto
Journal:  Mol Cell Biochem       Date:  2003-09       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.